About quanterix corp - QTRX
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.
QTRX At a Glance
Quanterix Corp.
900 Middlesex Turnpike, Building 1
Billerica, Massachusetts 01821
| Phone | 1-617-301-9400 | Revenue | 138.90M | |
| Industry | Medical Specialties | Net Income | -107,150,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 1.074% | |
| Fiscal Year-end | 12 / 2026 | Employees | 450 | |
| View SEC Filings |
QTRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.952 |
| Price to Book Ratio | 1.005 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.777 |
| Enterprise Value to Sales | 1.369 |
| Total Debt to Enterprise Value | 0.196 |
QTRX Efficiency
| Revenue/Employee | 308,660.00 |
| Income Per Employee | -238,111.111 |
| Receivables Turnover | 4.634 |
| Total Asset Turnover | 0.322 |
QTRX Liquidity
| Current Ratio | 2.839 |
| Quick Ratio | 2.107 |
| Cash Ratio | 1.581 |
QTRX Profitability
| Gross Margin | 46.768 |
| Operating Margin | -62.935 |
| Pretax Margin | -80.83 |
| Net Margin | -77.143 |
| Return on Assets | -24.848 |
| Return on Equity | -34.246 |
| Return on Total Capital | -32.18 |
| Return on Invested Capital | -31.162 |
QTRX Capital Structure
| Total Debt to Total Equity | 12.592 |
| Total Debt to Total Capital | 11.184 |
| Total Debt to Total Assets | 8.263 |
| Long-Term Debt to Equity | 9.915 |
| Long-Term Debt to Total Capital | 8.807 |